Platelet lysate based cell therapy - Celixir

Drug Profile

Platelet lysate based cell therapy - Celixir

Alternative Names: TendoncelTM

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celixir
  • Class Anti-inflammatories; Cell therapies
  • Mechanism of Action Angiopoietin replacements; Cell replacements; Fibroblast growth factor stimulants; Platelet derived growth factor replacements; Thrombospondin replacements; Vascular-endothelial-growth-factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tendon injuries

Most Recent Events

  • 13 Jun 2017 Celixir completes a phase II trial in Tendon injury (Tennis elbow) in Europe before June 2017 (Celixir pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top